Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113 CHF | +15.31% | -.--% | +15.31% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With a 2024 P/E ratio at 24.7 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.74 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.31% | 24.94B | - | ||
-5.43% | 182B | C+ | ||
+4.30% | 114B | C | ||
-3.09% | 68.38B | A | ||
+5.86% | 52.46B | B- | ||
+8.15% | 44.25B | B- | ||
+7.52% | 43.55B | B+ | ||
+25.54% | 32.69B | B | ||
+17.85% | 26.73B | A- | ||
+1.00% | 25.79B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- ZBH Stock
- Ratings Zimmer Biomet Holdings, Inc.